VeriDose^® DPYD Panel

Accurately Detect Key PGx Targets in the DPYD Gene

Partial or complete lack of dihydropyrimidine dehydrogenase (DPD) enzyme functionality can increase the risk of severe drug toxicity during treatment with fluoropyrimidines (5-FU, capecitabine, tegafur). Understanding DPYD gene status and its impact on drug metabolism is a rapidly growing focus area in clinical research.

The VeriDose^® DPYD Panel targets a set of 9 DPYD variants associated with an increased risk of severe toxicity, including the 5 variants recommended by the European Medical Agency and the 4 variants of primary relevance as noted by the Clinical Pharmacogenetics Implementation Consortium. The single well panel can be run either alone or side-by-side with other genotyping panels.

Panel Resources